Evidence map›Paper›PMID 42127413›Full record

ArticleSleep2026

Development and content validity of the Functional Impacts of Narcolepsy Instrument: a novel patient-reported outcome measure for narcolepsy type 1 and type 2.

Yulia Savva, Heather Romero, Stephen Crawford, Amy Howerter, Peter McPherson, Helen Doll, Tara Symonds, Todd Swick, Yves Dauvilliers

Abstract readValidation Study
In one paragraph

Article in Sleep, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yulia SavvaGlobal Medical Affairs - Neuroscience, Takeda Development Center Americas, Inc., Cambridge, MA, United States.
Heather RomeroGlobal Medical Affairs - Neuroscience, Takeda Development Center Americas, Inc., Cambridge, MA, United States.
Stephen CrawfordGlobal Medical Affairs - Neuroscience, Takeda Development Center Americas, Inc., Cambridge, MA, United States.
Amy HowerterProspective Studies, Clinical Outcomes Solutions, Tucson, AZ, United States.
Peter McPhersonQualitative Science, Clinical Outcomes Solutions, Folkestone, Kent, United Kingdom.
Helen DollQuantitative Science, Clinical Outcomes Solutions, Folkestone, Kent, United Kingdom.
Tara SymondsQualitative Science, Clinical Outcomes Solutions, Folkestone, Kent, United Kingdom.
Todd SwickGlobal Medical Affairs - Neuroscience, Takeda Development Center Americas, Inc., Cambridge, MA, United States.
Yves DauvilliersSleep-Wake Disorders Center, Department of Neurology, Gui-de-Chauliac Hospital, University of Montpellier, Montpellier, France.ORCID 0000-0003-0683-6506

Funding

Takeda Development Center Americas, Inc
6 · The paper itself

Abstract

STUDY

objectivesMost patient-reported outcome measures for narcolepsy focus on excessive daytime sleepiness or do not focus on specific disease impacts (e.g. cataplexy, cognitive difficulties, fatigue, daily function). The Functional Impacts of Narcolepsy Instrument (FINI) was developed to measure key functional impacts in people with narcolepsy type 1 and 2 (NT1/NT2).

methodsThe instrument was developed separately in NT1/NT2 populations with input from patients, clinical experts experienced in narcolepsy management, and clinical outcome scientists. Development included: patient experience interview studies informing item development; item development including de novo items, and modified/original items from the Patient-Reported Outcomes Measurement Information System (PROMIS) library; two waves of patient-debriefing interviews testing initial/modified item drafts; determination of scale structure using exploratory factor and Rasch analyses, and confirmatory factor analyses for NT2; consensus meetings between clinical sleep experts/clinical outcome experts to finalize the FINI draft items and structure with a 7-day recall period.

resultsThe final FINI for NT1 had 28 items within six independent domains: Tiredness, Cognitive Functioning, Cataplexy, Social Activities, Everyday Activities, and Everyday Responsibilities. The final NT2 version (FINI-NT2) included the same items excluding the Cataplexy domain (23 items). Final FINI and FINI-NT2 items demonstrated good content validity and covered the main impacts of NT1 and NT2, respectively, as confirmed by patient interviews, exploratory/confirmatory factor analyses, and Rasch analysis.

conclusionsThe novel FINI assesses key functional impacts of narcolepsy in people with NT1/NT2 for use across clinical settings, and adds to the number of existing clinical outcome assessments for central disorders of hypersomnolence. Statement of Significance People with narcolepsy type 1 (NT1) or narcolepsy type 2 (NT2) often experience impacts on their daily life, such as cognitive difficulties, fatigue, and impaired work/school responsibilities, leading to decreased quality of life. Despite these recognized challenges, there remains a need for an additional tool that measures functional outcomes and complements existing narcolepsy symptom, severity, and impacts assessments. The Functional Impacts of Narcolepsy Instrument (FINI) was developed to evaluate functional impacts of narcolepsy that are important and meaningful to people living with NT1 (FINI) and NT2 (FINI-NT2). The instrument offers a patient-centered outcome measure for assessing narcolepsy impacts and treatment benefits related to changes in functional outcomes that can be used in both the clinical trial setting and clinical practice.

Indexed as

NarcolepsyPatient Reported Outcome MeasuresAdultFemaleHumansMaleMiddle AgedPsychometricsQuality of LifeReproducibility of ResultsSurveys and QuestionnairesYoung Adultclinical outcome assessment, COAFINI-NT2Functional Impacts of Narcolepsy Instrument, FINInarcolepsyNT1NT2patient-reported outcome, PRO

Identifiers

PMID42127413
PMCPMC13472893

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.